Arbidol is a broad-spectrum antiviral drug, which is clinically used to treat influenza. In 21 this study, the pharmacokinetics, metabolism, and excretion of arbidol were investigated in 22 healthy male Chinese volunteers after a single oral administration of 200 mg of arbidol 23 hydrochloride. A total of 33 arbidol metabolites were identified in human plasma, urine, and 24 feces. The principal biotransformation pathways included sulfoxidation, dimethylamine 25 N-demethylation, glucuronidation, and sulfate conjugation. The major drug-related 26 component in the plasma was sulfinylarbidol (M6-1), followed by unmetabolized arbidol, 27 N-demethylsulfinylarbidol (M5), and sulfonylarbidol (M8). The exposures of M5, M6-1, and 28 M8, as determined by the metabolite-to-parent AUC 0-t ratio, were 0.9 ± 0.3, 11.5 ± 3.6, and 29 0.5 ± 0.2, respectively. In human urine, glucuronide and sulfate conjugates were detected as 30 the major metabolites, accounting for 6.3% of the dose excreted within 0 to 96 h after drug 31 administration. The fecal specimens mainly contained the unchanged arbidol, accounting for 32
was incubated in triplicate with pooled HLM, HIM, HKM, human cDNA-expressed P450sindividual P450 enzymes (50 pmol/ml), FMOs (4 pmol/ml), HLM (1 mg/ml), HIM (1 mg/ml), 183 or HKM (1 mg/ml), arbidol (5.0 µM or 50 µM), and NADPH (2.0 mM). Arbidol stock 184 solution was prepared in dimethyl sulfoxide (DMSO), and the final DMSO concentration in 185 the incubation was 0.1% (v/v). The reactions were initiated with the addition of NADPH, and 186 the incubations were performed at 37°C in a water bath. After 60 min of incubation, the 187 reactions were terminated with an equal volume of ice-cold acetonitrile. Control samples 188 without NADPH or substrate were included. The samples were analyzed using UPLC/Q-TOF 189
MS. 190
For the microsomal stability assay, arbidol, M5, M6-1, and M8 (each at 5.0 µM) were 191 individually incubated with HLMs in the presence of NADPH, using the same incubation 192 conditions described above. The reactions were terminated at 0 (T 0 ), 5.0, 15, 30, and 60 min. 193
The disappearance of test compound was monitored using UPLC/Q-TOF MS. 194 To estimate the contributions of the different P450 and FMO isoforms to the formation of 216 M5, M6-1, and M8 in human liver, the percentages of total normalized rate (% TNR) were 217 calculated as reported previously (11). This was done by multiplying the reaction rate of each 218 isoform by the specific protein content in HLMs to yield the "normalized rate" (NR), which 219 was expressed in pmol/min/mg microsomes. The NRs obtained were then summed up as the 220 "total normalized rate" (TNR The metabolic profiles of arbidol in plasma, urine and feces are shown in Fig. 1 . The 245 identified metabolic pathways of arbidol in humans are shown in Fig. 2 
Inhibition of P450s or FMOs in HLMs and

. 246
Urine. A total of 32 chromatographic peaks were observed in the urinary metabolic profile. 247
The peak at 23.0 min was assigned to unchanged arbidol because the retention time and mass 248 spectral fragmentation patterns were identical to those of arbidol. Likewise, the metabolite 249 peaks at 10.7, 14.9, 14.8, and 14.5 min (which contained two coeluted metabolites) were 250 Plasma. A total of 16 metabolites were detected in the human plasma extracts, and M6-1 285 was the major drug related component, followed by the unmetabolized arbidol. The other 286 metabolites that presented with relatively high levels in human plasma were M5 and M8.
conjugates were detected as minor metabolites. 292
Pharmacokinetics of Arbidol and Metabolites M5, M6-1, and M8. Table 2 presents the  293 pharmacokinetic parameters determined by noncompartmental analysis. The mean plasma 294 concentration versus time profiles for arbidol, M5, M6-1, and M8 are shown in Fig. 3 . After 295 oral drug administration, arbidol was rapidly absorbed with a mean t max of 1.38 h. M5 had a 296 comparable t max at 1.50 h, whereas the maximum plasma concentrations of M6-1 and M8 297 were reached much later at 13.0 h and 19.0 h, respectively. The mean t 1/2 values of the 298 metabolites were 26.3, 25.0 and 25.7 h, which were clearly longer than that of arbidol (15.7 h). 299
The sulfone metabolite M8 had the lowest concentration among the three major circulating 300 metabolites, with a mean C max of 22.7 ng/ml and a mean metabolite-to-parent AUC 0-t ratio 301
(AUC m /AUC p ) of 0.5 ± 0.2. The N-demethylsulfinyl compound M5 was the second most 302 abundant metabolite in circulation, with a C max of 80.5 ng/ml and a moderate AUC m /AUC p of 303 0.9 ± 0.3. The sulfinyl metabolite M6-1 was the major circulating species with a C max of 525 304 ng/ml and the highest AUC m /AUC p at 11.5 ± 3.6. In the mean plasma concentration-time 305 profiles of arbidol, a second peak was observed at about 3 h, it was not resulted from the 306 enterohepatic recirculation, but because of the inter-individual variability in T max . 307
In Vitro Metabolism of Arbidol. Human microsomes. Biotransformation of arbidol (at 308 concentrations of 5.0 µM and 50 µM) was investigated in HLMs, HIMs, and HKMs. Five 309 prominent metabolites, namely, M3-2, M5, M6-1, M7, and M8, were formed in HLMs and 310 HIMs (Fig. 4) , whereas only trace amounts of M6-1 were detected in HKMs. At the arbidol 311 concentration of 5.0 µM in HLMs, the parent drug was extensively metabolized, and the 312 amounts of metabolites formed followed the order of M3-2 > M5 > M7 > M6-1 > M8. At thepresence of NADPH. It was found that M5, M6-1 and M8 were metabolized mainly via 320 N-demethylation and/or sulfoxidation. The CL int values were calculated to be 116, 23.6, 28.9, 321 and 46.6 ml/min/kg for arbidol, M5, M6-1, and M8, respectively (Table 3 ). According to the 322 classification criteria (12, 13), M5 and M6-1 were categorized as medium-clearance 323 compounds, whereas arbidol and M8 were high-clearance compounds, and the most labile 324 compound was arbidol, which had a CL int value of 109 ml/min/kg. 325
Recombinant P450 and FMO isoforms. A series of cDNA-expressed P450s and FMOs were 326 used to evaluate the contribution of individual enzymes to arbidol metabolism. Each isoform 327
showed varying degrees of efficiency in the production of oxidative metabolites (Fig. 5 ). 328
Among those tested, FMOs were only responsible for sulfoxidation, whereas P450s were not 329 only involved in the formation of M6-1 and M8, but also of M5 and M7. Isoforms that 330
showed elevated levels of M6-1 production included CYP1A2, CYP2C19, CYP2D6, 331 CYP2E1, CYP3A4, CYP3A5, FMO1, FMO3, and FMO5, with FMO1 as the most efficient 332 isoform. The same array of P450s also contributed to the formation of M5, M7 and M8. P450 333 isoforms such as CYP1A1, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP4A11 334
were not involved in the metabolism of arbidol. In adult humans, FMO1 is primarily found in 335 the kidney and intestines (14). Based on the microsomal incubation experiments, the FMO1 336 contribution to the formation of M6-1 was mainly attributed to the FMO1 expressed in the 337 intestine, not in the kidney. The kinetic parameters for arbidol metabolism by P450s and 338 FMO3 were scaled to a typical human liver, and it was calculated that CYP3A4 showed the 339 highest %TNR in the formation of sulfoxidation and N-demethylation metabolites (Table 4) . In the present study, the metabolism and excretion of arbidol were investigated in healthy 360 male volunteers after a single oral administration of 200 mg of arbidol hydrochloride. This 361 study is the first to report on the arbidol metabolites in human plasma and feces. A total of 31 362 metabolites were found and identified in urine, 24 in feces, and 16 in plasma. Arbidol was 363 mainly excreted in urine as phase II conjugates. The major urinary metabolites were 364 glucuronide arbidol (M18) and glucuronide sulfinylarbidol (M20-1 and M20-2), which 365 accounted for approximately 3.6% of the dose. The urinary excretion of sulfate conjugates 366 (M10, M11-2, M14-1, and M15) was estimated to be 2.7% of the dose. The urinary excretion 367 of parent drug was less than 0.1% of the dose. Similar to preclinical species (1), about 32.4% 368 of the total intake dose of arbidol was excreted unchanged within 0−96 h via feces. The 369 sulfate conjugate of arbidol (M10) was the major metabolite in human feces, accounted for 370 3.0% of the dose, and other metabolites (M5, M6-1, M8) represented <2% of the dose. 371
Because the reference materials for the conjugated metabolites were not available, the 372 amounts excreted of these phase II metabolites were semi-quantified using arbidol as 373 formation, and the inhibitory effects of 1-ABT was always greater than that of the heat 435 treatment (Fig. 7) . Therefore, P450s are the major enzymes involved in the arbidol 436 metabolism in human intestines, with FMOs contributing to a lesser degree. Overall, the in 437 vitro studies indicated that P450s mainly catalyzed arbidol metabolism by HLMs and HIMs 438 compared with FMOs, with CYP3A4 as the most active enzyme. It could be predicted that 439 there was metabolic DDI potential between arbidol and coadministrated drugs that are 440 CYP3A4 inhibitors or inductors. 441
In conclusion, arbidol undergoes extensive phase I and phase II metabolism in humans. on October 23, 2017 by guest
